This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: July 31st, 2008 - July 31st, 2009

This activity is no longer available for credit, however its content is still relevant for your educational needs.

Target Audience
This educational publication is designed for physicians, nurses, and pharmacists who wish to enhance their knowledge concerning the management of patients with newly diagnosed multiple myeloma.

Learning Objectives
At the completion of this activity participants should be able to:

• Discuss the use of novel agents thalidomide, lenalidomide, and bortezomib in the initial treatment of patients newly diagnosed with multiple myeloma (MM) who are candidates for stem cell transplant
• Discuss the use of these agents in combination with melphalan and prednisone for the initial treatment of patients newly diagnosed with MM who are ineligible for stem cell transplant
• Review the results of studies and study updates presented at the 2007 annual meeting of the American Society of Hematology using these agents in various combinations

Disclosure Statement
In direct response to the September 2004 ACCME Standards for Commercial Support, CME Consultants issued a conflict of interest policy dated January 2, 2005. The policy states that the disclosure of potential financial conflicts of interest within the last 12 months must be made and resolved prior to the date of the CME/CE activity where commercial support grants are to be used to fund the activity. The following conflicts have been managed and resolved through CME Consultants Independent Review Committee. Our intent is to assist learners in assessing the potential for bias in information that is presented during the CME/CE activity. The faculty is also aware it is their responsibility to inform the audience if discussion of any non-FDA-approved uses of pharmaceutical, medical equipment, prostheses, etc will be included in their presentation.

Faculty Disclosures
*Sagar Lonial, MD, is a consultant for Bristol-Myers Squibb, Celgene, Millennium, and Novartis, and has received research support from Bristol-Myers Squibb, Celgene, Gloucester, Millennium, and Novartis.

Tiffany Andrews, MS, ANP, AOCNP is on the speaker's bureau for Celgene and Millennium.

Rowena Schwartz, PharmD, BCOP has nothing to disclose.


*Content will include non-FDA-approved uses.

Disclaimer
The contents of some CME activities may contain discussion of off-label uses of some of the agents mentioned. Please consult the prescribing information for full disclosure of approved uses.